Patient satisfaction with finasteride in the treatment of symptomatic benign prostatic hyperplasia

被引:7
|
作者
Kaplan, SA
Olsson, CA
机构
[1] Columbia-Presbyterian Medical Center, New York, NY
[2] Columbia-Presbyterian Medical Center, New York, NY 10032, 622 W. 168th St.
关键词
D O I
10.1016/S0149-2918(96)80180-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The type and magnitude of urinary symptoms, the behavioral adjustments necessitated by such symptoms, and the degree of patient satisfaction with treatment and current health were evaluated in 102 men with symptomatic benign prostatic hyperplasia (BPH) who had been receiving finasteride for 9 to 12 months. We also evaluated these variables in a group of 109 men who had under one transurethral resection of the prostate (TURF) for symptomatic BPH 9 to 12 months before the study. A validated, patient-directed telephone questionnaire was used to solicit information. Men with BPH who continued to receive finasteride therapy for at least 9 months experienced considerable symptomatic relief during the first year of therapy, and reported a high degree of satisfaction with their urinary condition. Urinary symptoms either resolved or occurred only rarely in the majority of men treated with finasteride. Most of the BPH patients taking finasteride (78%) indicated that urinary symptoms did not restrict their participation in normal activities. Fifty-four percent of finasteride patients rated their current health as excellent or very good, and 87% indicated that their current condition represented an improvement over their pretreatment state. Responses in the men treated with TURF reinforced previous observations about the effectiveness of this treatment in men with symptomatic BPH. Thus in the appropriate patient group, finasteride represents an effective management option for symptomatic BPH.
引用
收藏
页码:73 / 83
页数:11
相关论文
共 50 条
  • [41] Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia
    Kuo, HC
    UROLOGIA INTERNATIONALIS, 1998, 60 (02) : 85 - 91
  • [42] Specialists disagree on finasteride use in benign prostatic hyperplasia
    Pirisi, A
    LANCET, 1998, 351 (9104): : 730 - 730
  • [43] Finasteride to prevent morbidity from benign prostatic hyperplasia
    Wasson, JH
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (09): : 612 - 613
  • [44] The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
    Lepor, H
    Williford, WO
    Barry, MJ
    Brawer, MK
    Dixon, CM
    Gormley, G
    Haakenson, C
    Machi, M
    Narayan, P
    Padley, RJ
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (08): : 533 - 539
  • [45] Development of a patient satisfaction with treatment questionnaire for benign prostatic hyperplasia (BPH-PSTQ)
    Barron, R
    Kotak, S
    VALUE IN HEALTH, 2006, 9 (03) : A55 - A55
  • [46] A Review of Laser Treatment for Symptomatic BPH (Benign Prostatic Hyperplasia)
    Shiva Madhwan Nair
    Marie Adrianne Pimentel
    Peter John Gilling
    Current Urology Reports, 2016, 17
  • [47] Treatment of benign prostatic hyperplasia with finasteride: Evidence from a meta-analysis
    Jiang, Tao
    Zhang, Ying
    Hu, Zhilin
    Jiang, Bin
    Hou, Xu
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2018, 17 (04) : 723 - 729
  • [48] Effects of finasteride on prostatic blood flow in patients with benign prostatic hyperplasia
    Frauscher, F
    Klauser, A
    Furthmueller, B
    Feuchtner, G
    Pingerra, G
    Horninger, W
    Bartsch, G
    JOURNAL OF UROLOGY, 2003, 169 (04): : 476 - 476
  • [49] alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia
    Hansen, BJ
    JOURNAL OF UROLOGY, 1996, 156 (01): : 184 - 184
  • [50] ALPHA-BLOCKADE IN THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
    ERI, LM
    TVETER, KJ
    JOURNAL OF UROLOGY, 1995, 154 (03): : 923 - 934